Vor Bio, Korro Bio, Insitro and Rallybio revealed plans to lay off chunks of their respective workforces in the latest job ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

While updated study results confirmed the drug lowers a target protein, the therapy's effect on clinical outcomes was less ...

A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic ...

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed ...

Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing ...

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

Already facing headwinds caused by a patient’s death and treatment delays, the biotech now may have to contend with a less ...

The advisory committee meeting is an important step in the process of readying boosters for the fall and winter season, but ...